Lymph Node Evaluation for Colon Cancer in an Era of Quality Guidelines: Who Improves?
Overview
Affiliations
Introduction: In the 1990s, several organizations began recommending evaluation of > 12 lymph nodes during colon resection because of its association with improved survival. We examined practice implications of multispecialty quality guidelines over the past 20 years recommending evaluation of ≥ 12 lymph nodes during colon resection for adequate staging.
Materials And Methods: We used the 1988 to 2009 Surveillance, Epidemiology, and End Results program to conduct a retrospective observational cohort study of 90,203 surgically treated patients with colon cancer. We used Cochran-Armitage tests to examine trends in lymph node examination over time and multivariate logistic regression to identify patient characteristics associated with guideline-recommended lymph node evaluation.
Results: The introduction of practice guidelines was associated with gradual increases in guideline-recommended lymph node evaluation. From 1988 to 1990, 34% of patients had > 12 lymph nodes evaluated, increasing to 38% in 1994 to 1996 and to > 75% from 2006 to 2009. Younger, white patients and those with more-extensive bowel penetration (T3/4 nonmetastatic) and high tumor grade saw more-rapid increases in lymph node evaluation (P < .001). Multivariate analyses demonstrated a significant interaction between year of diagnosis and both T stage and grade, indicating that those with higher T stage and higher grade were more likely to receive guideline-recommended care earlier.
Conclusion: The implementation of lymph node evaluation guidelines was accepted gradually into practice but adopted more quickly among higher risk patients. By identifying patients who are least likely to receive guideline-recommended care, these findings present a starting point for promoting targeted improvements in cancer care and further understanding underlying contributors to these disparities.
Lymphatic system regulation of anti-cancer immunity and metastasis.
Lei P, Fraser C, Jones D, Ubellacker J, Padera T Front Immunol. 2024; 15:1449291.
PMID: 39211044 PMC: 11357954. DOI: 10.3389/fimmu.2024.1449291.
Dekkers N, Dang H, Vork K, Langers A, van der Kraan J, Westerterp M Cancers (Basel). 2023; 15(18).
PMID: 37760458 PMC: 10526268. DOI: 10.3390/cancers15184490.
Tumor Location as a Prognostic Factor in T1 Colorectal Cancer.
Ichimasa K, Kudo S, Kouyama Y, Mochizuki K, Takashina Y, Misawa M J Anus Rectum Colon. 2022; 6(1):9-15.
PMID: 35128132 PMC: 8801246. DOI: 10.23922/jarc.2021-029.
Alexander M, Lin J, Shriver C, McGlynn K, Zhu K Dis Colon Rectum. 2019; 63(3):346-356.
PMID: 31842166 PMC: 7021218. DOI: 10.1097/DCR.0000000000001555.
Minarich M, Schwarz R J Gastrointest Surg. 2019; 23(2):393-401.
PMID: 30603860 DOI: 10.1007/s11605-018-4056-7.